All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2017-12-14T15:40:24.000Z

ASH 2017 | BGB-3111 BTK inhibitor use in patients with indolent and aggressive NHL

Dec 14, 2017
Share:

Bookmark this article

The 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) took place in Atlanta, GA, on 9–12 December 2017. On Saturday December 9th, an oral abstract session was held on “Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Indolent Lymphomas, Novel Therapies, and Diagnostics”. This session was moderated by Jonathon B. Cohen, Emory University - Winship Cancer Institute and Craig A. Portell, University of Virginia.

Abstract #152 was presented during this session, titled “Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non-Hodgkin’s Lymphoma” by Constatine S. Tam, Peter MacCallum Cancer Centre & St. Vincent's Hospital, Melbourne, Australia and colleagues.

Study highlights

  • Overall, 99 patients with relapsed or refractory B-cell malignancies were included in the Phase Ib study split into two groups:
    • Aggressive lymphoma (AL): 27 diffuse large B-cell lymphoma (DLBCL), 38 mantle cell lymphoma (MCL)
    • Indolent lymphoma (IL): 24 follicular lymphoma (FL), 10 marginal zone lymphoma (MZL)
  • Patients were treated with Bruton’s Tyrosine Kinase (BTK) inhibitor zanubrutinib (BGB-3111), 160 mg twice daily

Efficacy

  • In total, 84 patients were assessed for treatment efficacy including objective response rate (ORR), complete response (CR) and partial response (PR)
    • ORR in indolent lymphoma patients (n = 26): 14 (54%)
      • ORR in FL patients (n = 17): 7 (41%)
      • ORR in MZL patients (n = 9): 7 (78%)
    • ORR in aggressive lymphoma patients (n = 58): 36 (62%)
      • ORR in DLBCL patients: 8 (31%)
      • ORR in MCL patients: 28 (88%)

Safety

  • Grade ≥3 adverse events (AEs) 38% from the IL arm, 60% from the AL arm had more than one
  • Serious AE: 32% of the IL patients and 40% of the AL patients had more than one serious AE
  • One fatal AE occurred in the IL cohort and six patients died due to AEs in the AL group

The authors concluded that BGB-3111 had an acceptable safety profile and was shown to have good clinical activity in both indolent and aggressive NHL subtypes, which is being further evaluated in phase II trials. AEs led to discontinuation in 10% of patients overall.

Watch the full interview with Constantine Tam discussing the BGB-3111 trial here. 

  1. Tam C. et al. Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Patients with Indolent and Aggressive Non-Hodgkin’s Lymphoma. Oral Abstract #152: ASH 59th Annual Meeting and Exposition, December 2017, Atlanta, GA.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
60 votes - 48 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox